Lincoln Pharmaceuticals Intrinsic Value
Lincoln Pharmaceuticals intrinsic value. Lincoln Pharmaceuticals (LINCOLN) median intrinsic value is ₹445.17 from 9 valuation models (range ₹170–₹758), vs current price ₹567.20 — -21.5% downside (Trading Above Calculated Value), margin of safety -27.4%. For current market price and key ratios, visit LINCOLN screener.
LINCOLN Valuation Methods Summary — DCF, Graham Number & P/E
Lincoln Pharmaceuticals intrinsic value across 9 models vs current price ₹567.20 — upside/downside and value range per method. Read Lincoln Pharmaceuticals dividend payments for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹511.28 | ₹409.02 - ₹613.54 | -9.9% | EPS: ₹23.24, Sector P/E: 22x |
| Book Value Method | asset | ₹758.00 | ₹682.20 - ₹833.80 | +33.6% | Book Value/Share: ₹379.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹732.00 | ₹658.80 - ₹805.20 | +29.1% | Revenue/Share: ₹366.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹420.00 | ₹378.00 - ₹462.00 | -26.0% | EBITDA: ₹84.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹480.22 | ₹384.18 - ₹576.26 | -15.3% | CF Growth: 7.7%, Discount: 15% |
| PEG Ratio Method | growth | ₹170.16 | ₹153.14 - ₹187.18 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹359.06 | ₹323.15 - ₹394.97 | -36.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹283.60 | ₹255.24 - ₹311.96 | -50.0% | ROE: 6.3%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹445.17 | ₹400.65 - ₹489.69 | -21.5% | EPS: ₹23.24, BVPS: ₹379.00 |
LINCOLN Intrinsic Value vs Market Price — All Valuation Models
Lincoln Pharmaceuticals fair value range ₹170–₹758 vs current market price ₹567.20 across 9 valuation models. Compare with LINCOLN DCF valuation to assess whether the stock is under or overvalued.
LINCOLN Intrinsic Value Analysis — Undervalued or Overvalued?
Lincoln Pharmaceuticals median intrinsic value ₹445.17, current price ₹567.20 — Trading Above Calculated Value by 21.5%, margin of safety -27.4%.
What is the intrinsic value of LINCOLN?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Lincoln Pharmaceuticals (LINCOLN) is ₹445.17 (median value). With the current market price of ₹567.20, this represents a -21.5% variance from our estimated fair value.
The valuation range spans from ₹170.16 to ₹758.00, indicating ₹170.16 - ₹758.00.
Is LINCOLN undervalued or overvalued?
Based on our multi-method analysis, Lincoln Pharmaceuticals (LINCOLN) appears to be trading above calculated value by approximately 21.5%.
LINCOLN Financial Health — Key Ratios vs Industry Benchmarks
Lincoln Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 26.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 6.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.82x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
LINCOLN Cash Flow Quality — Operating & Free Cash Flow
Lincoln Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹93 Cr | ₹54 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹63 Cr | ₹35 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹39 Cr | ₹21 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹76 Cr | ₹37 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹69 Cr | ₹37 Cr | Positive Free Cash Flow | 8/10 |